Table 1.
Objective response by mRECIST predicts OS: retrospective analysis
| Firstauthor [ref.], year | Agents (study design) | ORR (mRECIST), % (n/totaln) | Median OS, months |
HR (95% CI) |
p value | |
|---|---|---|---|---|---|---|
| responder (CR + PR) | nonresponder (SD + PD) | |||||
| Ronot [2], 2014 | sorafenib | 28.1 (18/64) | 25.5 | 13.3 (SD) | N/A | <0.001 |
| (retrospective) | 5.7 (PD) | |||||
| Arizumi [3], 2014 | sorafenib | 22.8 (36/158) | 25.4 | 7.3 (PD) | N/A | <0.0001 |
| (retrospective) | 5.7 (short SD) | |||||
| Edeline [4], 2012 | sorafenib | 22.6 (12/53) | 18 | 8 | N/A | 0.013 |
| (retrospective) | ||||||
| Takada [5], 2015 | sorafenib | 13.1 (25/191) | 22.0 | 10.0 | N/A | 0.0117 |
| (retrospective) | ||||||
OS, overall survival; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval; N/A, not available.